What is Scancell?
Scancell is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutic vaccines for cancer and chronic infectious diseases. At the core of its operations is the proprietary ImmunoBody technology platform, which represents a significant departure from traditional ex vivo dendritic cell therapies. By engineering human antibodies to express specific helper cell and cytotoxic T-lymphocyte epitopes, Scancell effectively targets dendritic cells in vivo. This approach bypasses the logistical and financial burdens associated with patient-specific cell processing, offering a scalable and potent alternative for treating melanoma and other tumor types. The platform's versatility also extends to potential applications in addressing hepatitis and HIV, positioning Scancell as a versatile player in the global immunotherapy landscape.
How much funding has Scancell raised?
Scancell has raised a total of $19.6M across 2 funding rounds:
Debt
$7.8M
Share Placement
$11.8M
Debt (2020): $7.9M with participation from Vulpes and Redmile Funds
Share Placement (2020): $11.8M led by Undisclosed
Key Investors in Scancell
Vulpes
A specialized investment firm with a focus on high-growth sectors, including life sciences and innovative technology ventures.
Redmile Funds
A prominent healthcare-focused investment manager known for supporting transformative clinical-stage biopharmaceutical companies.
Undisclosed Investors
What's next for Scancell?
With the recent capital infusion, Scancell is poised to intensify its clinical development efforts. The primary focus will remain on the progression of SCIB1, with the company aiming to generate robust data to support its efficacy in melanoma treatment. Beyond its lead asset, the firm is expected to leverage its ImmunoBody platform to expand its therapeutic pipeline, potentially exploring new indications in oncology and infectious disease. Strategic resource allocation will likely prioritize the optimization of manufacturing processes and the expansion of clinical trial sites to ensure a streamlined path toward regulatory approval. As the company matures, the focus will shift toward establishing commercial partnerships and validating the platform's broader utility in the competitive biotech market.
See full Scancell company page
